Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Most B2B professionals expect their firm's marketing budget will either increase or stay the same in 2025, according to recent research from Sagefrog. The report was based on data from a survey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback